Viatris Inc Intrinsic Value Calculator – Analysts Weigh in on Viatris Inc: Will It Outperform the Market?
November 16, 2023
🌥️Trending News
Analysts are weighing in on Viatris Inc ($NASDAQ:VTRS), asking the question whether the company’s stock will outperform the market. Viatris Inc is a global healthcare company that merges two industry leaders, Mylan and Upjohn, to form one of the world’s leading generics and specialty medicine providers. With its commitment to quality, access and affordability, Viatris Inc has the potential to make a positive impact in the lives of millions of customers around the world. Analysts are bullish about the company’s prospects and have given it ratings of “Buy” or “Strong Buy”.
Furthermore, the company has a strong balance sheet, with solid cash flow and an enviable portfolio of products and services. Despite any potential risks, analysts remain confident that Viatris Inc will continue to outpace the market in the future.
Stock Price
On Tuesday, Viatris Inc stock opened at 9.1 and closed at 9.2, up 3.0% from its last closing price of 9.0. Furthermore, the company has also experienced strong growth in its revenues, with a 12% increase over the previous year. With these strong fundamentals and an improving market outlook, many analysts believe that Viatris Inc is well positioned to outperform the market. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Viatris Inc. More…
| Total Revenues | Net Income | Net Margin |
| 15.6k | 1.85k | 12.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Viatris Inc. More…
| Operations | Investing | Financing |
| 2.5k | 843.4 | -3.37k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Viatris Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 48.7k | 27.85k | 17.38 |
Key Ratios Snapshot
Some of the financial key ratios for Viatris Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.7% | 9.0% | 20.1% |
| FCF Margin | ROE | ROA |
| 13.1% | 9.4% | 4.0% |
Analysis – Viatris Inc Intrinsic Value Calculator
At GoodWhale, we have conducted an analysis on VIATRIS INC‘s fundamentals. Through our proprietary Valuation Line, we have come to the conclusion that the intrinsic value of a VIATRIS INC share is around $11.7. Currently, the stock is trading at $9.2, indicating an undervaluation of 21.2%. This presents an opportunity for investors to capitalize on, as the stock is significantly undervalued and therefore presents a good potential for growth. More…
Peers
The company has a rich history of more than 150 years, dating back to the founding of its predecessor companies, which include some of the world’s most well-known brands. Today, Viatris is a leading provider of essential medicines and solutions, with a presence in more than 150 countries and a workforce of over 30,000 people. The company’s mission is to provide access to high-quality medicines and solutions for patients and customers around the world. Viatris is committed to being a trusted partner for patients, customers, employees, shareholders, and society. The company’s products are available in a wide range of therapeutic areas, including cardiovascular, diabetes, oncology, respiratory, and other conditions. Viatris has a portfolio of more than 1,000 products, including many that are essential medicines. The company also offers a range of services, including manufacturing, distribution, and logistics, to support its customers and patients. Viatris’s competitors include Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, and other global pharmaceutical companies.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is an American multinational pharmaceutical corporation. It is one of the world’s largest pharmaceutical companies. The company was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York. The company’s headquarters are in New York City. The company’s products include medicines and vaccines for a wide range of medical conditions and diseases.
– Teva Pharmaceutical Industries Ltd ($NYSE:TEVA)
Teva Pharmaceutical Industries Ltd is a pharmaceutical company with a market cap of 9.07B as of 2022 and a Return on Equity of -9.35%. The company focuses on producing generic drugs and active pharmaceutical ingredients. Teva is the world’s largest manufacturer of generic drugs and one of the world’s largest pharmaceutical companies.
– GSK PLC ($LSE:GSK)
GlaxoSmithKline PLC is a British pharmaceutical company with a market capitalization of 58.8 billion pounds as of 2022. The company has a return on equity of 34.04%. GlaxoSmithKline is a global healthcare company that researches, develops, and manufactures pharmaceuticals, vaccines, and consumer healthcare products.
Summary
Viatris Inc is a healthcare company with operations around the world. Investing analysis of Viatris Inc has been positive, with many analysts rating the stock favorably. The stock has performed well relative to the market, with a consistent increase in its stock price. Investors should consider the company’s track record of consistent growth and financial performance, and be aware of any potential risks associated with the stock.
Additionally, its size and diversity provide a degree of resilience in uncertain economic times. While the stock may experience ups and downs, overall Viatris Inc is expected to outperform the broader market in the long term.
